AbCellera announced Monday that an experimental, non-hormonal drug significantly reduced the frequency and severity of hot flashes in a mid-stage trial [1, 2].
The development offers a potential alternative for women who cannot or choose not to use traditional hormone replacement therapy, which is associated with various health risks [1, 3].
The Vancouver-based biotechnology company released the data from its Phase 2 trial on Aug. 10, 2026 [2]. The treatment targets the symptoms of menopause without utilizing hormones, aiming to provide a safer option for those suffering from hot flashes and anxiety [3].
AbCellera said its experimental menopause treatment significantly reduced the frequency and severity of hot flashes in the trial [2]. Dr. Pauline M. Maki, a senior author, said the magnitude of the effect was interesting [3].
Market reaction to the announcement was immediate. Shares of AbCellera surged by nearly 40% in early-morning trading following the release of the trial results [2].
While the company's results provide a new lead in menopause care, the drug remains experimental and has not yet received final regulatory approval for general use [2]. This distinguishes it from other non-hormonal options that may already be available on the market through different manufacturers [2].
Adrian Ghobrial, a reporter for CTV News, said the drug developed by AbCellera is providing hope to many women suffering through symptoms [1].
“The experimental menopause drug developed by Vancouver-based AbCellera is providing hope to many women suffering through symptoms.”
The emergence of non-hormonal alternatives for menopause symptoms addresses a significant gap in women's healthcare. Because hormone replacement therapy is contraindicated for some patients due to risks of blood clots or certain cancers, a proven non-hormonal mechanism would expand treatment accessibility and provide a clinically validated path for symptom management without endocrine manipulation.
